Qualigen Therapeutics (FRA:7R90) Buildings And Improvements : €0.00 Mil (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Qualigen Therapeutics Buildings And Improvements?

Qualigen Therapeutics Buildings And Improvements Historical Data

The historical data trend for Qualigen Therapeutics's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qualigen Therapeutics Buildings And Improvements Chart

Qualigen Therapeutics Annual Data

Trend

Mar20

Dec21

Dec22

Dec23

Buildings And Improvements

Qualigen Therapeutics Quarterly Data
	Sep19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Buildings And Improvements	Get a 7-Day Free Trial															-	-	-	-	-

Qualigen Therapeutics Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

Qualigen Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qualigen Therapeutics Inc (FRA:7R90) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

QLGN:USA

Address

5857 Owens Avenue, Suite 300, Carlsbad, CA, USA, 92008

Website

https://www.qlgntx.com

Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.

Qualigen Therapeutics Headlines

No Headlines